Abeona Therapeutics, Inc. (ABEO)
5.40
-0.03
(-0.55%)
USD |
NASDAQ |
Sep 25, 16:00
5.405
0.00 (0.00%)
After-Hours: 19:59
Abeona Therapeutics Enterprise Value : 182.07M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 182.07M |
| September 24, 2026 | 183.78M |
| September 23, 2026 | 189.51M |
| September 22, 2026 | 206.10M |
| September 21, 2026 | 197.52M |
| September 18, 2026 | 191.79M |
| September 17, 2026 | 192.94M |
| September 16, 2026 | 180.35M |
| September 15, 2026 | 186.07M |
| September 14, 2026 | 183.78M |
| September 11, 2026 | 182.92M |
| September 10, 2026 | 186.64M |
| September 09, 2026 | 204.38M |
| September 08, 2026 | 207.82M |
| September 04, 2026 | 216.40M |
| September 03, 2026 | 212.40M |
| September 02, 2026 | 213.54M |
| September 01, 2026 | 215.26M |
| August 31, 2026 | 207.82M |
| August 28, 2026 | 211.82M |
| August 27, 2026 | 218.69M |
| August 26, 2026 | 216.97M |
| August 25, 2026 | 228.42M |
| August 24, 2026 | 219.84M |
| August 21, 2026 | 221.55M |
| Date | Value |
|---|---|
| August 20, 2026 | 214.11M |
| August 19, 2026 | 223.84M |
| August 18, 2026 | 225.56M |
| August 17, 2026 | 212.97M |
| August 14, 2026 | 215.54M |
| August 13, 2026 | 236.14M |
| August 12, 2026 | 299.95M |
| August 11, 2026 | 296.52M |
| August 10, 2026 | 299.38M |
| August 07, 2026 | 287.36M |
| August 06, 2026 | 267.90M |
| August 05, 2026 | 262.18M |
| August 04, 2026 | 263.33M |
| August 03, 2026 | 238.72M |
| July 31, 2026 | 240.44M |
| July 30, 2026 | 243.30M |
| July 29, 2026 | 229.56M |
| July 28, 2026 | 217.55M |
| July 27, 2026 | 223.84M |
| July 24, 2026 | 219.26M |
| July 23, 2026 | 238.15M |
| July 22, 2026 | 240.44M |
| July 21, 2026 | 246.73M |
| July 20, 2026 | 243.87M |
| July 17, 2026 | 273.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ultragenyx Pharmaceutical, Inc. | 2.333B |
| ACADIA Pharmaceuticals, Inc. | 2.677B |
| Alnylam Pharmaceuticals, Inc. | 33.91B |
| Anika Therapeutics, Inc. | 259.45M |
| Savara, Inc. | 884.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 11.38M |
| Total Expenses (Quarterly) | 31.57M |
| EPS Diluted (Quarterly) | -0.3539 |
| Gross Profit Margin (Quarterly) | 57.45% |
| Profit Margin (Quarterly) | -177.4% |
| Earnings Yield | -20.79% |
| Normalized Earnings Yield | -21.40 |